Arrayus Technologies Awarded Funding to Advance Focused Ultrasound Therapy through AI
Summary
TORONTO, Jan. 18, 2023 /CNW/ - Arrayus Technologies Inc., an innovator in focused ultrasound therapy for oncology, announced today it has been awarded funding of up to $1.9 million from INOVAIT and the Government of Canada through the INOVAIT Focus Fund to develop and integrate machine learning and artificial intelligence capabilities into its therapy platform.Arrayus, a clinical-stage medical technology company, has developed a versatile focused ultrasound device that uses the energy of targeted ultrasound waves to destroy tissue and produce other biological effects deep in the body without making any incisions. The company believes this will offer both patients and providers significant advantages, including faster, safer treatments and expanded patient eligibility.With the funding contribution from the INOVAIT focus fund, and in collaboration with Sunnybrook Research Institute and Vancouver Coastal Health, Arrayus will use machine learning and automation tools to develop AI-enhanced treatment planning and control algorithms for focused ultrasound therapy. "Focused ultrasound therapy has the ability to radically improve the way cancer is treated", said James OReilly, Arrayus chief executive officer. Incorporating two decades of innovations by leaders in the field, the companys proprietary focused ultrasound technology combines a unique flat phased array design with advanced imaging and therapy monitoring for unprecedented treatment control and flexibility. For more information, visit www.arrayus.ca Established in 2020, INOVAIT invests strategically in collaborative partnerships that build upon strength in digital innovation and health science research to create a critical mass of world leading Image-Guided Therapy (IGT) companies.